ERCC1基因多态性与晚期非小细胞肺癌患者铂类化疗疗效的关系  

Association between Polymorphisms of ERCC1 and Response in Patients with Advanced Non-small Cell Lung Cancer Receiving Cisplatin-based Chemotherapy

作　　者：王敬慧[1] 张权[1] 张卉[1] 王群慧[1] 杨新杰[1] 顾艳斐[1] 张树才[1] 

机构地区：[1]北京胸科医院肿瘤内科,北京101149

出　　处：《中国肺癌杂志》2010年第4期337-341,共5页Chinese Journal of Lung Cancer

摘　　要：背景与目的有关ERCC1基因多态性是否影响接受含铂化疗的晚期非小细胞肺癌患者疗效及生存的研究结果不相一致。本研究前瞻性研究90例接受含铂方案化疗的初治晚期非小细胞肺癌患者ERCC1基因C8092A和第118位密码子多态性与疗效的关系。方法全部患者均接受含铂联合方案化疗,采用测序法对患者基因型进行分型,比较不同基因型与疗效的关系。结果ERCC1C8092A基因型频率分别为CC40.0%(36/90)、CA48.9%(44/90)、AA11.1%(10/90),第118密码子基因型频率分别为CC58.9%(53/90)、CT34.4%(31/90)、TT6.7%(6/90)。C8092ACC基因型有效率与CA、AA基因型无统计学差异(33.3%vs29.6%,P=0.71),ERCC1118CC基因型患者有效率与CT和TT基因型无统计学差异(32.1%vs24.3%,P=0.43)。C8092ACC基因型患者与CA和AA基因型PFS无统计学差异(5.2个月vs5.4个月,P=0.62),ERCC1118CC基因型患者CT和TT基因型PFS无统计学差异(5.5个月vs5.3个月,P=0.59)。结论ERCC1C8092A、118多态性可能与晚期非小细胞肺癌患者铂类化疗疗效无明显相关性。Background and objective Results of studies on genetic polymorphisms of ERCC1 gene in DNA repair pathway which may affect response to platinum-based chemotherapy and survival in patients with non-small cell lung cancer are conflicting.The aim of this study is to prospectively assess the association between single nucleotide polymorphisms of C8092A and codon118 in ERCC1 and drug response in 90 patients with advanced non-small cell lung cancer treated with cisplatin-based chemotherapy.Methods All patients were treated with cisplatin-based chemotherapy.Genotypes of ERCC1 C8092A and codon118 were examined by sequencing,and the association between genotypes and response was evaluated.Results Genotype frequencies of ERCC1 C8092A were CC 40.0% （36/90）,CA 48.9% （44/90） and AA 11.1% （10/90）,frequencies of codon118 were CC 58.9% （53/90）,CT 34.4% （31/90） and TT 6.7% （6/90）.There was no significant difference in response rate of patients carrying with CC,compared with CA plus AA in C8092A （33.3% vs 29.6%,P=0.71）.Response rate of patients carrying with CC in ERCC1 118 was 32.1%,24.3% with CT plus CC （P=0.43）.There was no difference in progression free survival between patients carrying with CC and CT plus TT in C8092A （5.2 months vs 5.4 months,P=0.62）.There was no difference in progression free survival between patients carrying with CC and CA plus AA （5.5 months vs 5.3 months,P=0.59）.Conclusion The results suggest that there is no association between polymorphisms in ERCC1 C8092A and codon118 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy.

关 键 词：肺肿瘤 化疗 ERCC1 多态性 

分 类 号：R734.2[医药卫生—肿瘤]